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                                        Renal cell cancer, the 14th most common cancer worldwide (  1  ), 
accounts for approximately 2% of all new cancer cases (  2  ) and 
approximately 102    000 deaths worldwide (  3  ). Rates have 
increased in Europe and the United States over the past 30 
years, in part because of improved imaging technologies but also 
because of other factors (  2  ). For example, cigarette smoking and 
obesity may each account for more than 20% of the cases of 
renal cell cancer. Increases in the incidence of renal cell carci-
noma and in the average age of patients with advanced renal cell 
carcinoma are predicted because of the aging population (  4  ). 
Although a higher risk of cancer is associated with advanced age, 
older patients are frequently underrepresented in oncology 
trials (  5  ). Thus, there is a lack of detailed data on how this 
important subgroup of patients tolerates and responds to emerg-
ing cancer therapies. 
  The perception that older patients are at higher risk for toxicity 
and less likely to beneﬁ  t from treatment has itself contributed to a 
lower accrual rate of older patients in these trials (  6  ). Physician 
surveys have found that comorbid conditions and toxic effects of 
treatment are the most frequently cited barriers to recruitment of 
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     Background     The perception that older cancer patients may be at higher risk than younger patients of toxic effects from 
cancer therapy but may obtain less clinical benefit from it may be based on the underrepresentation of 
older patients in clinical trials and the known toxic effects of cytotoxic chemotherapy. It is not known how 
older patients respond to targeted therapy.   
     Methods     This retrospective subgroup analysis of data from the phase 3, randomized Treatment Approach in Renal 
Cancer Global Evaluation Trial examined the safety and efficacy of sorafenib in older (age   ≥  70 years, n = 115) 
and younger patients (age <70 years, n = 787) who received treatment for advanced renal cell carcinoma. 
Patient demographics and progression-free survival were recorded. Best tumor response, clinical benefit rate 
(defined as complete response plus partial response plus stable disease), time to self-reported health status 
deterioration, and toxic effects were assessed by descriptive statistics. Health-related quality of life was assessed 
with a Cox proportional hazards model. Kaplan  –  Meier analyses were used to summarize time-to-event data.   
     Results     Median progression-free survival was similar in sorafenib-treated younger patients (23.9 weeks; hazard 
ratio [HR] for progression compared with placebo = 0.55, 95% confidence interval [CI] = 0.47 to 0.66) and 
older patients (26.3 weeks; HR = 0.43, 95% CI = 0.26 to 0.69). Clinical benefit rates among younger 
and older sorafenib-treated patients were also similar (83.5% and 84.3%, respectively) and were superior 
to those of younger and older placebo-treated patients (53.8% and 62.2%, respectively). Adverse events 
were predictable and manageable regardless of age. Sorafenib treatment delayed the time to self-reported 
health status deterioration among both older patients (121 days with sorafenib vs 85 days with placebo; 
HR = 0.66, 95% CI = 0.43 to 1.03) and younger patients (90 days with sorafenib vs 52 days with placebo; 
HR = 0.69, 95% CI = 0.59 to 0.81) and improved quality of life over that time.   
     Conclusions     Among patients with advanced renal cell carcinoma receiving sorafenib treatment, outcomes of older (  ≥  70 
years) and younger (<70 years) patients were similar.   
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older patients (  7  ,  8  ). A growing body of data, however, indicates 
that older patients with adequate organ function and a reasonable 
life expectancy should receive the same treatment as younger 
patients. A retrospective analysis (  9  ) of 401 patients from 19 studies 
that evaluated 13 different molecularly targeted cancer therapies 
found similar frequencies of drug-related adverse events among 
patients who were younger than 65 years and those who were 65 
years or older, regardless of whether the therapies were adminis-
tered as monotherapy or in combination with chemotherapy. 
Similarly, older patients with non  –  small-cell lung cancer who were 
70 years or older tolerated cisplatin-based regimens as well as 
younger patients, with response rates and time to progression simi-
lar to those of younger patients (  10  ). 
  Although more data are needed, current evidence indicates 
that age has a minimal inﬂ  uence on the nature and treatment of 
advanced renal cell carcinoma. Older (>70 years) and younger 
(  ≤  70 years) patients diagnosed with renal cell carcinoma present 
with similar clinical and laboratory features, incidences of 
nephrectomy, and probabilities of survival (  11  ). A moderately 
greater mortality rate has been observed in some older patient 
populations with advanced renal cell carcinoma, perhaps because 
older patients in these studies were at a more advanced stage at 
diagnosis (  12  ). In another analysis (  13  ), older patients (  ≥  60 
years; n = 174) with advanced renal cell carcinoma who received 
subcutaneous cytokine-based therapy (either interleukin-2 or 
interferon-2     therapy) had similar objective response rates 
(27% vs 31%), median overall survival (22 vs 19 months), and 
median progression-free survival (6 vs 5 months), as younger 
patients (<60 years; n = 251). 
  Sorafenib (Nexavar, Bayer HealthCare Pharmaceuticals, 
Montville, NJ) is a novel multikinase inhibitor with antiangio-
genic and proapoptotic activity. Sorafenib inhibits such tyrosine 
kinases as vascular endothelial growth factor receptor-1, -2, 
and -3; platelet-derived growth factor receptor-    ; c-Kit; and Flt-3 
(  14  ). Sorafenib, an oral agent, was approved as a treatment for 
renal cell carcinoma in the United States in December 2005 on 
the basis of results of the pivotal phase 3 Treatment Approach in 
Renal Cancer Global Evaluation Trial (TARGET), the largest 
randomized placebo-controlled trial in renal cell carcinoma to 
date. The ﬁ  nal independently assessed analysis (  15  ), as of January 
2005, found a statistically signiﬁ  cant doubling of progression-free 
survival from 2.8 to 5.5 months (  P   < .001) for sorafenib-treated 
patients and a clinically meaningful trend toward improved overall 
survival (median = 14.7 months in the placebo group compared 
with median not reached in sorafenib group; hazard ratio [HR] of 
death from any cause = 0.72,   P   = .018). Because of the statistically 
signiﬁ   cantly improved progression-free survival, trend toward 
improved overall survival, and manageable toxicity proﬁ  le, the 
trial was stopped early and patients who had been randomly 
assigned to receive placebo were allowed to cross over to treat-
ment with sorafenib. The ﬁ  nal progression-free survival data sup-
ported global approval of sorafenib, the ﬁ   rst systemic agent 
approved for renal cell carcinoma in over a decade. In this retro-
spective analysis of data collected before placebo patients were 
allowed to cross over to sorafenib therapy, we evaluated the asso-
ciation of age with results of treatment with sorafenib in patients 
with advanced renal cell carcinoma by comparing outcomes 
between younger (<70 years) and older (  ≥  70 years) patients 
enrolled in TARGET. 
    Materials and Methods 
    Eligibility 
  The study population in TARGET consisted of patients who were 
at least 18 years of age with histologically confirmed metastatic 
renal cell carcinoma. Patients with disease progression after they 
received at least one systemic treatment for metastatic renal cell 
carcinoma (within the previous 8 months) were enrolled in the 
study. Other eligibility criteria included Eastern Cooperative 
Oncology Group performance status of 0 or 1; a Memorial Sloan-
Kettering Cancer Center prognostic score indicating low or inter-
mediate risk; and adequate bone marrow, liver, pancreatic, and 
renal function. Patients with brain metastases were excluded from 
the study. All patients provided written informed consent before 
study entry in accordance with the institutional review board of 
each participating institution.   
    Study Design 
  This was a retrospective analysis of outcomes in patients younger 
than 70 years or 70 years or older who were a part of the pivotal 
phase 3 double-blind international randomized parallel-group 
    CONTEXT AND CAVEATS 
    Prior knowledge 
  It was not known how older patients would respond to molecularly 
targeted therapy.   
    Study design 
  Retrospective subgroup analysis of data from a phase 3 random-
ized trial that examined the safety and efficacy of sorafenib in 115 
older (age   ≥  70 years) and 787 younger (age <70 years) patients 
with advanced renal cell carcinoma.   
    Contribution 
  Median progression-free survival and clinical benefit rates (ie, com-
plete response + partial response + stable disease) were similar in 
younger and older sorafenib-treated patients and better than those 
of younger and older placebo-treated patients. Adverse effects 
were predictable and manageable regardless of age. Sorafenib 
treatment delayed the time to self-reported health status deteriora-
tion in both groups and improved quality of life over that time.   
    Implications 
  Results of this study support the use of sorafenib as a treatment 
for advanced renal cell carcinoma in all age groups.   
    Limitations 
  The study was not designed to test for statistically significant dif-
ferences between treatment effects in younger and older sub-
groups. The sample size in the older group was limited, and there 
was an imbalance in treatment assignments in the older group. 
Older patients who participate in clinical trials are generally health-
ier than those who do not participate, and so results of this study 
may not be generalizable. 
    From the Editors       
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multicenter TARGET, which compared sorafenib treatment with 
placebo treatment in patients with advanced renal cell carcinoma 
who had received one previous regimen of systemic therapy. The 
details of the TARGET trial design are reported elsewhere (  15  ). 
Briefly, from November 24, 2003, when the first patient was 
assessed for eligibility, until March 31, 2005, when enrollment 
closed, 903 patients were enrolled and randomly assigned to receive 
either sorafenib or placebo treatment. There were 451 patients in 
the sorafenib group and 452 in the placebo group. Baseline disease 
characteristics (  see   Table 1) were collected at the time of study entry 
in the clinic and recorded on the study case report forms in con-
junction with treatment group randomization. Patients were strati-
fied by country and Memorial Sloan-Kettering Cancer Center 
prognostic score and then were randomly assigned to treatment 
with 400 mg of sorafenib twice daily or with placebo (in 6-week 
cycles for the first 24 weeks and 8-week cycles thereafter) in a con-
tinuous dosing fashion until progressive disease or unacceptable 
toxicity was encountered.         
  Because 115 patients in this study were aged 70 years or older, 
this population provided a rare opportunity to assess the beneﬁ  ts 
and side effects of treatment in the elderly. Consultations with 
clinicians in the ﬁ  eld of geriatrics indicated that 70 years was the 
age beyond which individuals tend to be classiﬁ  ed as elderly. 
  A single planned, independently assessed analysis of progression-
free survival in January 2005 (  15  ) found that sorafenib was associ-
ated with a statistically signiﬁ   cant increase in progression-free 
survival (HR for disease progression = 0.44, 95% conﬁ  dence inter-
val [CI] = 0.35 to 0.55,   P   < .001, with the median progression-free 
survival of the sorafenib group being double that of the placebo 
group  —  ie, 24 vs 12 weeks, respectively). Consequently, crossover 
from placebo to sorafenib was permitted beginning in May 2005. 
The data in this report are from an updated descriptive analysis of 
progression-free survival as of May 2005, after the trial was fully 
accrued but before crossover was allowed.   
    Outcome Variables 
  The outcome variables for this retrospective analysis included 
progression-free survival, best tumor response, clinical benefit rate, 
and quality of life. A complete response was defined as disappear-
ance of all target lesions. A partial response was defined as a 30% 
decrease in the sum of the longest diameter of target lesions. Stable 
disease was defined as small changes in lesions that did not meet 
criteria for complete response, partial response, or progressive dis-
ease. Progression-free survival was defined as the time from ran-
domization to disease progression (as detected radiologically or 
clinically, whichever was earlier) or death (if death occurred before 
progression). Tumor assessments by computed tomography or 
magnetic resonance imaging of the chest, abdomen, and pelvis were 
performed before treatment, on day 1 of cycle 2, and at every cycle 
thereafter until the end of treatment. Tumor response was assessed 
by Response Evaluation Criteria in Solid Tumors (  16  ). Clinical 
benefit rate was defined as the proportion of patients with a com-
plete response, a partial response, or stable disease. 
  Patient-reported quality of life outcomes were assessed by use 
of the Functional Assessment of Cancer Therapy –  Kidney Symptom 
Index (FKSI) and the Physical Well-Being (PWB) domain of the 
Functional Assessment of Cancer Therapy  –  General version 
(FACT-G) (  17  ,  18  ). FKSI measures patient-reported kidney 
cancer  –  related symptoms and concerns. The PWB domain of 
FACT-G measures the physical functioning aspect of quality of 
life. In general, higher scores mean a better quality of life, with a 
change in an individual’s score of 4 points considered a meaningful 
difference. The questionnaires were administered on day 1 of each 
cycle and at the end of treatment visit. 
  Safety analysis measured treatment-related adverse events; it 
distinguished between drug-related vs non  –  drug-related events. 
Adverse events were graded by use of the Common Terminology 
Criteria for Adverse Events from the National Cancer Institute. 
Quality of life data were obtained during the ﬁ  rst ﬁ  ve cycles of 
treatment.   
    Statistical Methods 
  The subgroup analyses were conducted among the intent-to-treat 
older and younger subgroups and included data obtained through 
May 2005. Statistical analyses were performed in an exploratory 
fashion and their results are mainly descriptive in nature. Toxic 
effects were evaluated by use of the Common Terminology Criteria 
for Adverse Events version 3.0, and all events referred to were treat-
ment related. Descriptive statistics were used to describe patient 
characteristics, best tumor response, clinical benefit rate, and safety 
for patients who were younger than 70 years or 70 years or older by 
treatment group. Kaplan  –  Meier estimates and curves were used to 
summarize time-to-event data, such as the analysis of progression-
free survival. Treatment-related differences in response were evalu-
ated by the Cochran  –  Mantel  –  Haenszel test. Progression-free 
survival was compared by the log-rank test (stratified by prognostic 
group and country). 
  The median time to health status deterioration was calculated 
for FKSI and the PWB domain of FACT-G by use of the Cox 
proportional hazards model. Schoenfeld residual plots were used 
to evaluate the proportional hazard assumption. For FKSI and 
PWB, the median time to health status deterioration was deﬁ  ned 
as a 4-point drop in total score from FKSI-15 or PWB or as clini-
cal progression, or death if the FKSI-15 or PWB score was miss-
ing. A 4-point drop in total score was chosen to be consistent with 
published data on what constitutes a clinically signiﬁ  cant deterio-
ration. Details of the number of assessments completed at each 
time point and the mean scores for FKSI-15 and PWB have been 
described elsewhere (  17  ). In addition, the condition of patients was 
rated as improved, no change, or worsened, according to how their 
scores compared with baseline for each cycle, on the basis of a 
4-point change for total score of FKSI-15 and PWB scores. All 
reported   P   values are two-sided.     
    Results 
  From November 24, 2003, through March 31, 2005, 903 patients 
were randomly assigned to receive treatment with sorafenib (n = 
451) or placebo (n = 452). Of these 903 patients, 902 received a study 
drug and were evaluated for safety in this analysis. Of the 115 
patients who were 70 years or older, 70 were randomly assigned to 
receive sorafenib and 45 were assigned to placebo. Of the 788 
patients who were younger than 70 years, 381 were randomly 
assigned to sorafenib and 407 were assigned to placebo (  Figure 1  ). jnci.oxfordjournals.org    JNCI | Articles 1457
Baseline characteristics for the two age groups are listed in   Table 1  . 
The median age of older sorafenib-treated patients was 72 years 
(range = 70  –  86 years) and that of older placebo-treated patients was 
73 years (range = 70  –  84 years). There were no clinically significant 
differences in baseline characteristics between sorafenib arms, except 
that older patients had a higher proportion of female patients, an 
increased proportion of patients with Eastern Cooperative Oncology 
Group performance scores of 1 or 2, and more patients with an 
inter    mediate risk according to the Memorial Sloan-Kettering 
Cancer Center criteria. At baseline, older sorafenib-treated patients 
had higher incidences of vascular hypertensive disorders (66% vs 
36%), diabetes mellitus (20% vs 11%), coronary artery disorders 
(7% vs 6%), anemias (14% vs 7%), and breathing abnormalities 
(16% vs 9%) than younger sorafenib-treated patients.         
    Efficacy 
  The best tumor response was determined among patients by age 
and treatment (  Table 2  ). Among 381 younger patients randomly 
assigned to receive sorafenib, 33 (8.7%) had a partial response and 
285 (74%) had stable disease. Among younger patients randomly 
assigned to receive placebo, six (1.5%) had a partial response and 
213 (52%) had stable disease. Among the 70 older sorafenib-treated 
patients, one (1.4%) had a complete response, 10 (14%) had a par-
tial response, and 48 (69%) had stable disease. The difference in 
overall response rates (complete response plus partial response) 
between the treatment groups for younger patients (8.7% in the 
sorafenib-treated group and 1.5% in the placebo-treated group; 
difference = 7.2%, 95% CI = 4.3% to 11%) was lower than that for 
older patients (15.7% in the sorafenib-treated group and 4.4% in 
the placebo-treated group; difference = 11.3%, 95% CI = 10.5% to 
17%), as calculated by the Cochran  –  Mantel  –  Haenszel test. Among 
older patients who were randomly assigned to receive placebo, two 
(4.4%) had partial response and 26 (58%) had stable disease. The 
clinical benefit rate (complete response + partial response + stable 
disease) for older and younger patients receiving sorafenib (84.3% 
and 83.5%, respectively) was substantially higher than in those 
receiving placebo (62.2% and 53.8%, respectively).         
  Progression-free survival among sorafenib-treated patients was 
approximately double that observed among placebo-treated 
patients, regardless of age (  Figure 2  ). Among older sorafenib-
treated patients, the median progression-free survival was 26.3 
weeks, and among older placebo-treated patients, the median was 
13.9 weeks (HR of progression = 0.43; 95% CI = 0.26 to 0.69). 
Median progression-free survival among sorafenib-treated younger 
patients was 23.9 weeks and that among younger placebo-treated 
patients was 11.9 weeks (HR = 0.55, 95% CI = 0.47 to 0.66). The 
progression-free survival outcomes for older sorafenib-treated 
patients were thus consistent with the results in younger patients 
and in the overall TARGET population (  15  ).         
  Progression-free survival beneﬁ  ts should be considered in the 
context of the cost to the patient of achieving such beneﬁ  ts. One 
way to estimate the net degree of patient beneﬁ  t is to compare the 
length of therapy among patient and treatment groups estimated 
from the start to the end of study drug therapy. Among patients 
younger than 70 years, the median duration of sorafenib therapy was 
25.6 weeks and of placebo treatment was 15.7 weeks (difference = 9.9 
weeks; 95% CI = 9.83 to 9.97 weeks). Among patients who were 70 
years or older, the median duration of sorafenib therapy was 24.1 
weeks and of placebo treatment was 18.8 weeks (difference = 5.3 
weeks; 95% CI = 4.77 to 5.83 weeks).   
    Toxicity 
  All patients who were assessable for toxic effects were analyzed by 
age group and treatment (  Table 3  ). The overall incidence of 
adverse events of any grade among younger sorafenib-treated 
patients was 94.2%, among older sorafenib-treated patients was 
98.6%, among younger placebo-treated patients was 85.7%, and 
among older placebo-treated patients was 86.7%. Approximately 
  Figure 1    .       CONSORT trial ﬂ  ow dia-
gram. Patient enrollment and out-
comes are shown for all patients 
with renal cell carcinoma (aged <70 
or   ≥  70 y) who were randomly ass-
igned to treatment with sorafenib or 
placebo. An intent-to-treat analysis 
was used.       1458   Articles | JNCI  Vol. 100, Issue 20  |  October 15, 2008
half of the adverse events among both younger (47.7%) and older 
(40.0%) sorafenib-treated patients were grades 1 and 2. Slightly 
more grade 3 and 4 toxic effects were reported in older sorafenib-
treated patients than in younger sorafenib-treated patients (for 
grade 3 events, 40.0% vs 29.4%, respectively; and for grade 4 
events, 5.7% vs 7.3%, respectively).         
  The most common adverse events that were observed in at least 
10% of sorafenib-treated patients are shown in   Table 4  . Older 
patients had slightly more gastrointestinal symptoms than younger 
patients; younger patients had a higher incidence of sorafenib-
related hypertension, sensory neuropathy, and pruritus than did 
older patients. More older patients than younger patients experi-
enced fatigue.         
  The most frequently reported adverse events among older 
sorafenib-treated patients were rash or desquamation, diarrhea, 
alopecia, fatigue, hand  –  foot skin reaction, and anorexia. These 
events were primarily grades 1 and 2 and were medically manage-
able. There were no unexpected adverse events attributable to 
advanced age. Cardiac events, a particular concern in older patients 
treated with antiangiogenic agents, among older sorafenib-treated 
patients vs older placebo-treated patients, respectively, were as fol-
lows: grade 4 cardiac ischemia/infarction (one vs zero patients), 
grade 5 cardiac ischemia or infarction (two vs zero patients), and 
grade 3 left ventricular systolic dysfunction (one vs zero patients). 
  Thirty-one (8.1%) younger and 15 (21.4%) older sorafenib-
treated patients permanently discontinued treatment, whereas 350 
  Table 1    .       Baseline patient characteristics by age for patients with renal cell carcinoma in the Treatment Approach in Renal Cancer Global 
Evaluation Trial (TARGET)  *     
    Characteristic
Age <70 y Age   ≥  70 y
Total 
(n = 903) 
  Sorafenib 
(n = 381)
Placebo 
(n = 407)
Sorafenib 
(n = 70)
Placebo 
(n = 45)   
    Male, No. (%) 271 (71.1) 305 (74.9) 44 (62.9) 35 (77.8) 655 (72.5) 
  Female, No. (%) 110 (28.9) 102 (25.1) 26 (37.1) 10 (22.2) 248 (27.5) 
  Median age, y (range) 57 (19  –  69) 58 (29  –  69) 72 (70  –  86) 73 (70  –  84) 59 (19  –  86) 
  Disease states, No. (%)  
         Anemia 28 (7) 43 (11) 10 (14) 3 (7) 84 (9) 
         Breathing abnormalities 33 (9) 43 (11) 11 (16) 5 (11) 92 (10) 
         CAD 21 (6) 21 (5) 5 (7) 7 (16) 54 (6) 
         DM 42 (11) 48 (12) 14 (20) 9 (20) 113 (13) 
         Vascular hypertens. disorder 137 (36) 138 (34) 46 (66) 27 (60) 348 (39) 
  MSKCC risk, No. (%)  
         Low 201 (53) 200 (49) 32 (46) 28 (62) 461 (51) 
         Intermediate 180 (47) 206 (51) 38 (54) 17 (38) 441 (49) 
  Baseline ECOG performance score, No. (%)  
         0 190 (50) 185 (46) 29 (41) 25 (56) 429 (49) 
         1 184 (49) 216 (53) 39 (56) 20 (44) 459 (49) 
         2 5 (2) 4 (1) 2 (3) 0 11 (1) 
  Baseline site of metastasis, No. (%)    †     
         Lung 297 (78) 309 (76) 51 (73) 39 (87) 696 (77) 
         Liver 93 (24) 106 (26) 23 (33) 11 (24) 233 (26) 
         Bone 79 (21) 86 (21) 17 (24) 11 (24) 193 (21) 
  Tumor sites, No. (%)  
         1 52 (14) 54 (13) 10 (14) 9 (20) 125 (14) 
         2 112 (29) 117 (29) 19 (27) 12 (27) 260 (29) 
           ≥  3 215 (56) 235 (58) 41 (59) 24 (53) 515 (57) 
         Missing 2 (1) 1 (0) 0 (0) 0 (0) 3 (0) 
  Time since initial diagnosis    ‡    , y (range) 1.7 (0.1  –  19.4) 1.8 (0.1  –  19.9) 1.7 (0.4  –  16.2) 2.2 (0.3  –  8.3) 1.7 (0.1  –  19.9) 
  Stage at initial diagnosis, No. (%)  
         I 28 (7) 35 (9) 8 (11) 9 (20) 80 (9) 
         II 69 (18) 62 (15) 8 (11) 3 (7) 142 (16) 
         III 112 (29) 129 (32) 27 (39) 18 (40) 286 (32) 
         IV 164 (43) 174 (43) 25 (36) 14 (31) 377 (42) 
         Missing 8 (3) 7 (1) 2 (3) 1 (2) 18 (1) 
  Clear-cell histology,  §   No. (%) 379 (99) 402 (99) 70 (100) 45 (100) 896 (99) 
  Prior nephrectomy, No. (%) 359 (94) 377 (93) 63 (90) 44 (98) 843 (93) 
  Previous IL-2/IFN,    ||     No. (%) 321 (84) 332 (82) 53 (76) 36 (80) 742 (82)   
    *     CAD = ischemic coronary artery disorders; DM = diabetes mellitus; ECOG = Eastern Cooperative Oncology Group; IL-2 = interleukin-2; IFN = interferon; 
MSKCC = Memorial Sloan-Kettering Cancer Center; hyperthens. = hypertensive.   
      †       Patients may be included in more than one category.   
      ‡       Data were not available for all patients. Data were available as follows: 377 sorafenib-treated patients <70 y, 399 placebo-treated patients <70 y, 
68 sorafenib-treated patients   ≥  70 y, 44 placebo-treated patients   ≥  70 y, and 888 total patients.   
    §     Histology could encompass more than one category.   
      ||       Patients who had previously received immunotherapy with interleukin-2 and/or interferon.     jnci.oxfordjournals.org    JNCI | Articles 1459
(91.8%) younger and 55 (78.6%) older patients tolerated treat-
ment. For younger patients, discontinuation was most commonly 
attributed to pulmonary or upper respiratory (2.1%, or eight 
patients) and constitutional (1.3%, or ﬁ  ve patients) disorders (eg, 
fatigue or fever), whereas older patients discontinued sorafenib 
mostly because of gastrointestinal (5.7%, or four patients) and 
dermatologic (4.3%, or three patients) issues. Additionally, dose 
reductions occurred in 43 (11.3%) younger and 15 (21.4%) older 
sorafenib-treated patients, most frequently as a result of dermato-
logic adverse events (6.6%, or 25 patients) of younger and (8.6%, 
or six patients of older patients, most commonly hand  –  foot skin 
reaction), followed by gastrointestinal events (2.9%, or 11 patients, 
vs 5.7%, or four patients, most commonly diarrhea), and general 
cardiac issues (1.0%, or four patients, vs 4.3%, or three patients, 
most commonly for hypertension). Hematologic events were rare 
(<5%) among sorafenib-treated patients, with the only exception 
being anemia in the older subgroup (11.4%, or eight patients) and 
in younger patients (6.8%, or 26 patients).   
    Quality of Life 
  Among younger patients, the median number of days to health 
status deterioration as measured by the FKSI-15 tool was 90 days 
for sorafenib-treated patients and 52 days for placebo-treated 
patients (HR = 0.69, 95% CI = 0.59 to 0.81) (  Figure 3, B  ). When 
measured by PWB, medians were 93 and 73 days (HR = 0.69, 95% 
CI = 0.58 to 0.81) (  Figure 4, B  ). Among older patients, sorafenib 
treatment, compared with placebo treatment, also delayed the time 
to health status deterioration (121 vs 85 days, HR = 0.66, 95% CI = 
0.43 to 1.03, when measured by the FKSI-15 tool; and 126 vs 84 
days, HR = 0.65, 95% CI = 0.42 to 1.01, when measured by PWB), 
although neither delay was statistically significant (  Figures 3, A  , and 
  4, A  ).                 
  Table 2    .       Best tumor response by age group  *     
    Best response
Age <70 y Age   ≥  70 y 
  Sorafenib (n = 381) Placebo (n = 407) Sorafenib (n = 70) Placebo (n = 45)   
    Complete response (CR)  
         No. 0 0 1 0 
         Rate, % (95% CI) 0.0 (0.0 to 1.0) 0.0 (0.0 to 0.9) 1.4 (0.0 to 7.7) 0.0 (0.0 to 7.9) 
  Partial response (PR)  
         No. 33 6 10 2 
         Rate, % (95% CI) 8.7 (6.0 to 11.9) 1.5 (0.5 to 3.2) 14.3 (7.1 to 24.7) 4.4 (0.5 to 15.1) 
  Stable disease (SD)  
         No. 285 213 48 26 
         Rate, % (95% CI) 74.8 (70.1 to 79.1) 52.3 (47.4 to 57.3) 68.6 (56.4 to 79.1) 57.8 (42.2 to 72.3) 
  Progressive disease (PD)  
         No. 48 152 8 15 
         Rate, % (95% CI) 12.6 (9.4 to 16.4) 37.3 (32.6 to 42.2) 11.4 (5.1 to 21.3) 33.3 (20.0 to 49.0) 
  Clinical benefit (CR + PR + SD), % 83.5 53.8 84.3 62.2   
    *     Response Evaluation Criteria in Solid Tumors criteria were used to evaluate tumor responses. The 95% confidence intervals (CIs) for the difference in response 
rates (ie, complete response plus partial response) were based on the Cochran  –  Mantel  –  Haenszel test. Within-treatment 95% CIs were based on the exact 
binomial distribution.     
  Figure 2    .        Progression-free survival by age 
(<70 or   ≥  70 y) among patients with renal cell 
carcinoma who were treated with sorafenib 
or with placebo. The median survival and 
95% conﬁ   dence interval (CI) are shown as 
well as the hazard ratios (HRs) that compare 
progression in the sorafenib treatment group 
with that in the placebo treatment group. Sor = 
sorafenib; Pla = placebo.       1460   Articles | JNCI  Vol. 100, Issue 20  |  October 15, 2008
  In earlier treatment cycles (cycles 2 and 3), a similar proportion 
of patients in each treatment group were rated as improved, no 
change, or worsened on the basis of a 4-point change in the total 
FKSI-15 and PWB score from baseline, regardless of age. 
However, by treatment cycle 4, a higher proportion of younger 
sorafenib-treated patients were classiﬁ  ed as improved or no change 
than of younger placebo-treated patients (for the FKSI-15 tool, 
54.7% vs 31.8%; and for PWB, 56% vs 36.4%). Similarly, at cycle 
4, a higher proportion of older sorafenib-treated patients were 
classiﬁ  ed as either improved or no change than older placebo-
treated patients (for the FKSI tool, 57.8% vs 40.7%; for PWB, 
63.3% vs 42.4%). This trend in improvement or no change in 
FKSI and PWB scores, regardless of age, was also observed in 
cycle 5.     
    Discussion 
  In this retrospective subgroup analysis of TARGET data, sorafenib 
treatment appeared to improve outcomes among patients with 
advanced renal cell carcinoma, regardless of age. Analysis of pre-
crossover data indicated that for both older and younger patients, 
progression-free survival in the sorafenib group was approximately 
double that in the placebo group. Furthermore, the increased clini-
cal benefit rate was approximately equal for both younger and older 
patients. Additionally, side effects were expected, mild, and medi-
cally manageable. There was no notable difference in the frequency 
or severity of sorafenib-related toxicity between younger and older 
patients. 
  Sorafenib is a multikinase inhibitor that slows tumor growth by 
inhibition of intracellular signals in the Ras  –  Raf pathway and 
blocks receptor tyrosine kinases involved in tumor angiogenesis 
(  19  ). TARGET is the largest randomized placebo-controlled trial 
among patients with renal cell carcinoma, and its results supported 
the approval of sorafenib as a treatment for renal cell carcinoma. 
Older patients (ie, 70 years or older) constituted 12.7% of the 
TARGET study population. This subgroup analysis of the 
TARGET population showed that older and younger patients 
treated with sorafenib beneﬁ  ted equally, with double the progression-
free survival that was observed among placebo-treated patients. 
Interestingly, the magnitude of this beneﬁ  t was greater in older 
patients (26.3 vs 13.9 weeks) than in younger patients (23.9 vs 11.9 
weeks). This difference may be attributable to characteristics of the 
  Table 3    .       Overall treatment-emergent adverse events by worst grade in each age group   
    Grade
Age <70 y, No. (%) Age   ≥  70 y, No. (%) 
  Sorafenib (n = 381) Placebo (n = 406  *  )  P   value    †    Sorafenib (n = 70) Placebo (n = 45)   P   value    †       
    1 44 (11.5) 72 (17.7) .016 5 (7.1) 11 (24.4) .013 
  2 138 (36.2) 137 (33.7) .501 23 (32.9) 17 (37.8) .689 
  3 112 (29.4) 90 (22.2) .022 28 (40.0) 8 (17.8) .014 
  4 28 (7.3) 26 (6.4) .673 4 (5.7) 1 (2.2) .647 
  5 37 (9.7) 23 (5.7) .043 9 (12.9) 2 (4.4) .197 
  Total with any grade 359 (94.2) 348 (85.7) <.001 69 (98.6) 39 (86.7) .014   
    *     One of the 407 patients withdrew consent, leaving 406 patients.   
      †         P   values were obtained from Fisher exact test that was used to monitor for adverse safety signals at a statistical significance level of .05.     
  Table 4    .       Overall treatment-emergent adverse events with an incidence of 10% or higher by age   
    Adverse event
Age <70 y, No. (%) Age   ≥  70 y, No. (%) 
  Sorafenib (n = 381) Placebo (n = 406  *  )  P   value    †    Sorafenib (n = 70) Placebo (n = 45)   P   value    †       
    Constitutional  
         Fatigue 138 (36.2) 109 (26.8) .006 27 (38.6) 16 (35.6) .844 
         Weight loss 39 (10.2) 25 (6.2) .038 7 (10.0) 0 (0) .041 
  Dermatologic  
         Alopecia 101 (26.5) 11 (2.7) <.001 21 (30.0) 4 (8.9) .010 
         Dry skin 42 (11.0) 17 (4.2) <.001 8 (11.4) 1 (2.2) .088 
         Hand  –  foot skin reaction 118 (31.0) 26 (6.4) <.001 16 (22.9) 4 (8.9) .077 
         Pruritus 77 (20.2) 25 (6.2) <.001 8 (11.4) 4 (8.9) .763 
         Rash/desquamation 149 (39.1) 62 (15.3) <.001 31 (44.3) 8 (17.8) .005 
  Gastrointestinal  
         Anorexia 54 (14.2) 49 (12.1) .399 19 (27.1) 8 (17.8) .270 
         Constipation 54 (14.2) 43 (10.6) .130 14 (20.0) 6 (13.3) .453 
         Diarrhea 165 (43.3) 51 (12.6) <.001 30 (42.9) 7 (15.6) .002 
         Nausea 84 (22.0) 78 (19.2) .333 18 (25.7) 9 (20.0) .509 
  Other  
         Hypertension 69 (18.1) 8 (2.0) <.001 7 (10.0) 0 (0.0) .041 
         Sensory neuropathy 57 (15.0) 26 (6.4) <.001 2 (2.9) 3 (6.7) .378   
    *     One of the 407 patients withdrew consent, leaving 406 patients.   
      †         P   values were obtained from Fisher exact test that was used to monitor for an adverse safety signal at a statistical significance level of .05.     jnci.oxfordjournals.org    JNCI | Articles 1461
vasculature in the elderly population that make them more suscep-
tible to inhibition by agents targeting receptor tyrosine kinases. 
Preclinical evidence indicates that tumor vasculature in older ani-
mals is different from that in younger animals, with the vasculature 
in older animals having more and smaller vessels (  20  ). In addition, 
angiogenesis inhibitors have shown more pronounced antitumor 
effects and have resulted in a greater increase in survival among 
older xenograft mice than among younger xenograft mice (  21  ). 
  Before sorafenib approval for renal cell carcinoma, immuno-
therapy with interleukin-2 and/or interferon-     was the most fre-
quently used systemic treatment option. Individuals aged 65 years 
or older who received immunotherapy performed better than 
those aged 60  –  64 years, with longer progression-free survival (8 vs 
4 months) and overall survival (23 vs 20 months) (  13  ). Although 
older patients with renal cell carcinoma perform better on immu-
notherapy than younger patients, the limited disease control rate 
and the severe toxicity proﬁ  le render immunotherapy less attrac-
tive to use than the emerging targeted treatments, such as sorafenib 
(  22  ). That concept was conﬁ   rmed in this subanalysis, because 
patients older than 70 years with advanced renal cell carcinoma 
beneﬁ  ted from sorafenib treatment. 
  The most frequently reported adverse events in older sorafenib-
treated patients were rash or desquamation, diarrhea, alopecia, 
fatigue, hand  –  foot skin reaction, and anorexia. These events were 
mostly grades 1 and 2 and were medically manageable. No unex-
pected adverse events attributable to advanced age were observed. 
Cardiac ischemia or infarction and left ventricular dysfunction 
events are of particular concern in older patients treated with anti-
angiogenic and certain cytotoxic agents. Although not common, 
cardiac ischemia or infarction was reported in 10 (2.6%) younger 
sorafenib-treated patients but in only three (4.3%) older patients, 
and left ventricular dysfunction was observed in three younger 
patients but in only one older patient. 
  Although there is a reasonable concern that older patients may 
not tolerate cytotoxic or immunotherapy as well as younger 
patients, in the current subset analysis approximately 79% of older 
  Figure 3    .       Time to self-reported health status 
deterioration by age according to treatment 
(sorefenib vs placebo) as measured by the 
Functional Assessment of Cancer Therapy  –
  Kidney Cancer Symptom Index (FKSI).   A  ) 
Patients aged   ≥  70 y.   B  ) Patients aged <70 y. 
The median time to self-reported health sta-
tus deterioration and 95% conﬁ  dence interval 
(CI) is shown as well as the hazard ratios 
(HRs) that compare self-reported health sta-
tus deterioration in the sorafenib treatment 
group with that in the placebo treatment 
group. Sor = sorafenib; Pla = placebo.       1462   Articles | JNCI  Vol. 100, Issue 20  |  October 15, 2008
patients tolerated treatment with sorafenib. The mean duration of 
therapy was approximately 25 weeks, regardless of age. The most 
common adverse events among these patients were gastrointestinal 
(primarily diarrhea and nausea) and dermatologic (primarily rash, 
hand  –  foot syndrome, and alopecia). However, few of these events 
were grade 3 and/or 4. This result indicates that prophylactic and/
or maintenance treatment to control gastrointestinal and dermato-
logic symptoms may increase the proportion of older patients who 
can tolerate sorafenib to approach the level observed among 
younger patients (92%). In addition, cardiac events, a particular 
concern in older patients treated with antiangiogenic agents, were 
infrequent. 
  The quality of life (as measured by FKSI and FACT-G) of 
placebo-treated patients deteriorated more quickly than that of 
sorafenib-treated patients, regardless of age. In addition, sorafenib-
treated patients maintained or improved their quality of life at a 
later stage in therapy than placebo-treated patients. Thus, by 
accepted quality of life measures, sorafenib therapy resulted in 
maintained or improved quality of life. 
  This study had several limitations. The subgroup analyses in 
this study were conducted in a post hoc exploratory fashion, and 
interpretation of the results is subject to the following limitations 
of the data. This study was not designed to test for statistically 
signiﬁ  cant differences between treatment effects in the older and 
younger age subgroups. Other caveats that may inﬂ  uence interpre-
tation of results include a limited sample size and an imbalance in 
treatment assignment for the elderly subgroup. As with any sub-
group analysis, the limited sample size and imbalance in the treat-
ment assignment inﬂ  uence the strength of the observations, yet the 
data that we presented provide some important trends between 
treatment groups for key study data across the older and younger 
subgroups in TARGET. These analyses provide valuable informa-
tive results that will help clinicians to offer targeted therapy appro-
priately and that also provide some guidance in the design of trials 
involving targeted therapies. 
  Although exploratory in nature, this subgroup analysis of the 
pivotal TARGET trial demonstrated that sorafenib conferred a 
statistically signiﬁ   cant increase in progression-free survival and 
  Figure 4    .       Time to self-reported health status 
deterioration by age according to treatment 
(sorefenib vs placebo) as measured by the 
Physical Well-Being (PWB) domain of Functi-
onal Assessment of Cancer Therapy  –  General. 
  A  ) Patients aged   ≥  70 y.   B  ) Patients aged <70 
y. The median time to self-reported health 
status deterioration and 95% conﬁ  dence 
interval (CI) is shown as well as the hazard 
ratios (HRs) that compare self-reported health 
status deterioration in the sorafenib treat-
ment group with that in the placebo treat-
ment group. Sor = sorafenib; Pla = placebo.       jnci.oxfordjournals.org    JNCI | Articles 1463
increased clinical beneﬁ  t without compromising the quality of life 
of both older and younger patients with advanced renal cell carci-
noma. The efﬁ  cacy of sorafenib was maintained in patients who 
were 70 years or older. This result, combined with an acceptable 
toxicity proﬁ  le in both younger and older patients, supports the 
use of sorafenib as a treatment for advanced renal cell carcinoma 
in all age groups.         
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